Display options
Cite
Roggeri DP, Roggeri A, Rossi E, et al. Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs. Hepat Med. 2015;7:37-42doi: 10.2147/HMER.S87594.
Roggeri, D. P., Roggeri, A., Rossi, E., Cinconze, E., Gasbarrini, A., Monici Preti, P., & De Rosa, M. (2015). Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs. Hepatic medicine : evidence and research, 737-42. https://doi.org/10.2147/HMER.S87594
Roggeri, Daniela Paola, et al. "Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs." Hepatic medicine : evidence and research vol. 7 (2015): 37-42. doi: https://doi.org/10.2147/HMER.S87594
Roggeri DP, Roggeri A, Rossi E, Cinconze E, Gasbarrini A, Monici Preti P, De Rosa M. Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs. Hepat Med. 2015 Jul 13;7:37-42. doi: 10.2147/HMER.S87594. eCollection 2015. PMID: 26203290; PMCID: PMC4506032.
Copy Download .nbib Format: NLM
Share it on

Hepat Med. 2015 Jul 13;7:37-42. doi: 10.2147/HMER.S87594. eCollection 2015.

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs.

Hepatic medicine : evidence and research

Daniela Paola Roggeri, Alessandro Roggeri, Elisa Rossi, Elisa Cinconze, Antonio Gasbarrini, PierAlessandro Monici Preti, Marisa De Rosa

Affiliations

  1. ProCure Solutions, Nembro, Bergamo, Italy.
  2. CINECA, Interuniversity Consortium, Bologna, Italy.
  3. Catholic University of Sacred Heart, Policlinic A Gemelli, Rome, Italy.
  4. Alfa Wassermann, Bologna, Italy.

PMID: 26203290 PMCID: PMC4506032 DOI: 10.2147/HMER.S87594

Abstract

PURPOSE: Hepatic encephalopathy (HE) is a recurrent severe complication of progressive hepatic cirrhosis. The aim of this study is to evaluate the average annual direct healthcare costs for the treatment of patients with overt HE in Italy.

PATIENTS AND METHODS: This retrospective, observational study analyzed information from the database of ARNO Observatory. Patients with at least one hospitalization due to overt HE in the period from January 1, 2011 to December 31, 2011, were selected and observed during the year following the hospitalization. Costs for drugs, diagnostic and therapeutic procedures, and hospitalizations were estimated from the Italian National Health Service perspective.

RESULTS: Out of a population of 2,678,462 subjects, 381 patients were identified, of whom, 21.5% died during the first hospitalization and 5.8% during the follow-up; the survival rate was 72.7% at the end of the observation period. The direct healthcare costs per patient amounted to €13,393/year (15,295 USD) (88% for hospitalizations, 8% for drugs, and 4% for diagnostic procedures). During the follow-up, 42.5% of patients had at least one rehospitalization due to HE. Patients readmitted for HE had an average annual cost of €21,272 (24,293 USD), almost doubled if compared to patients without readmissions (€12,098 [13,816 USD]).

CONCLUSION: This analysis showed that patients with HE had relevant direct healthcare costs, in which hospitalizations were the most important cost drivers.

Keywords: costs; hepatic encephalopathy; hospitalizations; relapses

References

  1. JAMA. 2012 Jun 27;307(24):2589; author reply 2589-90 - PubMed
  2. Hepatology. 1998 Jul;28(1):45-9 - PubMed
  3. Am J Gastroenterol. 2001 Feb;96(2):579-83 - PubMed
  4. J Chronic Dis. 1987;40(5):373-83 - PubMed
  5. Hepatology. 2014 Aug;60(2):715-35 - PubMed
  6. Am J Gastroenterol. 2011 Sep;106(9):1646-53 - PubMed
  7. N Engl J Med. 2010 Mar 25;362(12):1071-81 - PubMed
  8. Clin Gastroenterol Hepatol. 2012 Sep;10(9):1034-41.e1 - PubMed
  9. Am J Gastroenterol. 2012 Feb;107(2):247-52 - PubMed
  10. Pharmacotherapy. 2009 Feb;29(2):138-53 - PubMed
  11. Aliment Pharmacol Ther. 2011 Oct;34(8):853-61 - PubMed
  12. Dig Dis Sci. 2003 Aug;48(8):1622-6 - PubMed
  13. J Clin Epidemiol. 2005 Apr;58(4):323-37 - PubMed
  14. J Hepatol. 1999 May;30(5):890-5 - PubMed

Publication Types